Cardiovascular and eletrocardiographic parameters after tonin administration in Wistar rats  by Damasceno, Denis D. et al.
Regulatory Peptides 181 (2013) 30–36
Contents lists available at SciVerse ScienceDirect
Regulatory Peptides
j ourna l homepage: www.e lsev ie r .com/ locate / regpepCardiovascular and eletrocardiographic parameters after tonin administration in
Wistar rats
Denis D. Damasceno a,b,⁎, Mercia P. Lima c, Daisy F. Motta b, Anderson J. Ferreira d, Judson F. Quintão-Junior e,
Lucas R. Drummond e, Antônio J. Natali e, Alvair P. Almeida b, Jorge L. Pesquero b
a Department of Educational Development, Federal Institute of Education, Science and Technology of Southeast Minas Gerais, Campus Barbacena, MG, Brazil
b Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
c Nursing School, Federal University of Minas Gerais, Belo Horizonte, Brazil
d Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
e Department of Physical Education, Biological Sciences and Health Center, Federal University of Viçosa, Viçosa, Minas Gerais, Brazil⁎ Corresponding author at: Department of Educational
José Augusto, 224, São José, 36.205-018, Barbacena, MG,
fax: +55 32 3693 8614.
E-mail address: denis.damasceno@ifsudestemg.edu.b
0167-0115 © 2013 Elsevier B.V.
http://dx.doi.org/10.1016/j.regpep.2012.12.009
Open access under the Elsea b s t r a c ta r t i c l e i n f oArticle history:
Received 15 April 2012
Received in revised form 12 October 2012
Accepted 17 December 2012
Available online 11 January 2013
Keywords:
Tonin
Renin–angiotensin system
Isolated heart
Electrocardiogram
Autonomic tonusIn order to understand the mechanisms of interaction between tonin–angiotensin and renin–angiotensin sys-
tems (RAS)we evaluated, “in vivo” and “in vitro”, inWistar rats, cardiovascular and electrocardiographic param-
eters after tonin administration. Arterial pressure (AP) and electrocardiogram (ECG) were recorded in awake
animals before and after tonin administration. Langendorff techniquewas used to analyze cardiac function in iso-
lated heart in the presence of tonin and video motion edge detection system was used to evaluate the effect of
tonin upon contractile function of isolated rat ventricular cardiomyocytes. After tonin infusion rats presented sig-
niﬁcantly higher diastolic and mean arterial pressure (MAP) and heart rate (HR) as compared with control. The
ECG analysis revealed shorter RR interval, increase in the low-frequency (LF) range of the heart rate variability
(HRV) power (%) and decrease in the high-frequency (HF) of HRV power (%). Isolated hearts perfused with
tonin presented an increase in the arterial coronary pressure (ACP) and decline in the ventricular systolic tension
(ST), maximal (dT/dt+) and minimal (dT/dt) contractility. The rates of contraction and relaxation of isolated
ventricular cardiomyocytes were signiﬁcantly increased due to the presence of tonin. The angiotensin II
(Ang II) levels in the coronary sinus efﬂuent increased in the presence of tonin in a dose-dependent manner
and the effect of tonin upon ACP was completely blocked by candesartan. Tonin is able to generate the vasocon-
strictor peptide Ang II in the isolated heart of the rat and the cardiovascular response induced by tonin was
completely blocked by candesartan, an indication that the action of Ang II on Ang II type 1 (AT1) receptors is
the major mechanism of the heart effects. Tonin affects cardiomyocyte contractile function which may be due
to interference with Ca2+ handling.
© 2013 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The renin-angiotensin system (RAS) is well known for its regulation
of blood pressure (BP) and ﬂuid homeostasis. The RAS participates in
changes in chronotropism, inotropism, arrhythmogenesis and cellular
growth in the heart [1]. Ang II, the effector of the system causes vaso-
constriction directly and indirectly by stimulating angiotensin II (Ang
II) type 1 (AT1) receptors present on the vasculature and by increasing
sympathetic tone [2]. All components of the RAS can be found in the
heart, vasculature, kidney, among others [3]. Even though some authors
speculate on the putative mechanism of renin uptake from the plasmaDevelopment, RuaMonsenhor
Brazil. Tel.: +55 32 3693 8625;
r (D.D. Damasceno).
vier OA license.into the heart, it is well described that renin synthesis in the heart is ap-
proximately 2% of that of the kidney [4].
The existence of alternative Ang II generating systems in different
sites of cardiovascular importance suggests diverse physiological
effects for these systems in the local control of blood ﬂow and in
the pathophysiology of hypertension and cardiovascular diseases [5].
These systems, involving proteinases other than renin and the angio-
tensin converting enzyme (ACE), have been shown in several species
including human [6–8].
An enzyme that represents a good candidate to be involved in the
Ang II generation as an alternative route is the serine proteinase
tonin, which is able to release Ang II directly from angiotensinogen
(AG) [9]. Tonin is present in many organs of the rat, such as the heart,
brain, prostate and submandibular gland [10–12]. Tonin may also re-
lease Ang II from peptides presenting the sequence corresponding to
the N-terminal portion of AG including angiotensin I (Ang I) and the
tetradecapeptide (AG(1–14)) [7], the synthetic renin substrate. The
31D.D. Damasceno et al. / Regulatory Peptides 181 (2013) 30–36observed speciﬁcity of the enzyme supports a possible important role of
tonin for local Ang II liberation in tissues [13].
In 2003, Borges [12] and collaborators presented evidences that
tonin may participate in the process of cardiac hypertrophy in the
rat. These authors showed that Wistar rats with isoproterenol-
induced cardiac hypertrophy presented increased levels of tonin
activity and expression of tonin and AG in the atria. No change was
observed in the levels of expression and activity of ACE or renin in
cardiac tissue of these animals when compared with the control
group. Therefore, to advance in the characterization of the physiolog-
ical role of tonin more recently our group generates transgenic mice
that express rat tonin (TGM(rTon)). These mice present high levels
of tonin mRNA and activity speciﬁcally in the brain. As a consequence,
TGM(rTon) develop increased BP and water intake [14].
In order to understand themechanisms of interaction between tonin–
angiotensin and RAS in the heart, we evaluated “in vivo” and “in vitro”
cardiovascular and electrocardiographic parameters of male Wistar rats
after tonin administration. Isolated working hearts were used to separate
the effects of the local and systemic RAS. In addition, the effect of tonin
upon contractile function of isolated rat cardiomyocytes was analyzed.
2. Experimental procedures
2.1. Animals
Experiments were performed in male Wistar rats (250–300 g)
from the main breeding stock of the Institute of Biological Sciences
(Federal University of Minas Gerais, Brazil). Animals were housed in-
dividually in plastic cages, under controlled light conditions (lights
on at 6:00 am and off at 8:00 pm), room temperature at 24 °C with
food and water ad libitum. Efforts were made to avoid any unneces-
sary distress to the animals and all animal procedures were performed
in accordance with institutional guidelines approved by the Ethics
Committee in Animal Experimentation of the Federal University of
Minas Gerais, Brazil (CETEA-UFMG), which are in accordance with
the National Institutes of Health (NIH) Guidelines for the Care and
Use of Laboratory Animals. The animals were randomly divided into
3 groups: a) in vivo group—BP, ECG and HR measurements, b) in
vitro group—for systolic and diastolic tension analysis in isolated
hearts and c) cardiomyocytes group, for contractile function determi-
nation in isolated ventricular myocytes.
2.2. Blood pressure
Twenty-four hours before the experiment the animals were anes-
thetized with 2.5% tribromoethanol (1 mL/100 g of body weight, i.p.,
Sigma-Aldrich, Inc.) and polyethylene catheters (PE-10 connected to
PE-50) were inserted into abdominal aorta through the left femoral ar-
tery and into the femoral vein for recording of BP and drug infusion, re-
spectively. The catheters were tunneled subcutaneously and
exteriorized backing the cervical region of the animal. Five Wistar rats
were used for BPmeasurements. Highly puriﬁed tonin [10]was injected
into the femoral catheter. MAP and systolic and diastolic arterial pres-
sure (SAP and DAP, respectively) were monitored simultaneously dur-
ing experiments by a solid-state strain gauge transducer (TSD 104A,
Biopac Systems, Inc., CA, USA). The transducer was connected to a com-
puter through a data acquisition system (MP100; Biopac Systems, Inc.,
CA, USA). The data were analyzed by the AcqKnowledge Software. The
experiments were conducted in conscious and freely moving rats.
2.3. Electrocardiogram and heart rate variability
To obtain ECG tracings ﬁve Wistar rats were anesthetized with 2.5%
tribromoethanol (1 mL/100 g of body weight, i.p., Sigma-Aldrich, Inc.)
and a bipolar platinumelectrodewas positioned in the thorax (subcuta-
neous tissue) directly in derivation DII [15]. The ECG recordings wereperformed 24 h after the implantation of the electrode and catheters.
Highly puriﬁed tonin [10] was injected into the femoral catheter. ECG
was evaluated in conscious, freely moving rats. The RR and PR intervals,
QT interval duration, corrected QT (QTc) and theQRS complexwere an-
alyzed. TheQT intervalwasmeasured starting from the onset of the QRS
complex until the end of the Twave,which is the return of the Twave to
the baseline. QTc was obtained using Bazett's formula (QTc=QT/√RR)
[16]. The HRVwas calculated by Kubios software from successive RR in-
terval obtained from the ECG tracings. In the time-domain analysis, the
following indexes were evaluated: standard deviation of RR intervals
(SDNN) and square root of the mean squared differences of successive
RR intervals (RMSSD). Additionally, in the frequency-domain analysis
of HRV the LF power (%) and the HF power (%) were evaluated [17].
2.4. Isolated hearts
ThirtyﬁveWistar ratswere used for cardiac function evaluation. The
hearts were isolated and perfused (8.0±0.2 mL/min) as previously de-
scribed [18]. All experiments were initiated after a 10-min stabilization
period. The drugs were dissolved in KRS (perfusion ﬂuid containing:
118.4 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4–7H2O,
2.5 mM CaCl2–H2O, 11.7 mM glucose and 26.5 mM NaHCO3) to obtain
the desired ﬁnal concentration. Highly puriﬁed tonin [10] was added to
the perfusing KRS to 8, 16, 32 and 64 ng/mL and administered to each
group separately. The dose of 32 ng/mL was administered in the pres-
ence or not of 1 nM candesartan. In the doses of 16 and 64 ng/mL,
the coronary sinus efﬂuent was collected (at 0, 5, 10, 15, 20, 25 and
30 min) and subsequently assayed for Ang II by speciﬁc radioimmuno-
assay [19]. Mechanical parameters such as systolic and diastolic ten-
sions and arterial coronary pressure (ACP) were measured throughout
the experiment. A force transducer (model FT3, Grass) was attached
through a heart clip to the apex of the ventricles to record the contrac-
tile force (tension, g) in a computer using a data acquisition system
(Biopac System, Inc., CA, USA). A diastolic tension of 1.0±0.1 g was ap-
plied to the hearts [20] and we also evaluated the tension developed by
the hearts by calculating the derivatives (±dT/dt) using the software
AcqKnowledge Version 3.5.7 (Biopac System, Inc., CA, USA). Maximum
dT/dt is a reasonable index of the initial velocity of myocardial contrac-
tion and minimum dT/dtwith myocardial relaxation.
2.5. Isolated cardiomyocyte
Left ventricular myocytes were isolated as previously described [21].
Cell contractile functionwas evaluated as previously described [21]. Brief-
ly, isolated cells were placed in a chamber with a glass coverslip base
mounted on the stage of an inverted microscope (Nikon Eclipse TS100).
Cells were perfused with HEPES Tyrode's solution containing 1 mM
CaCl2 plus 0, 10, 15 or 20 ng/mL of tonin, and ﬁeld stimulated at the fre-
quency of 1 Hz (20 V, 5 ms duration square pulses) via platinum bath
electrodes (MyoPacer ﬁeld stimulator; IonOptix, Milton, MA). Cells were
visualized on a personal computer monitor with a NTSC camera
(MyoCam; IonOptix) in partial scanning mode. This image was used to
measure cell shortening (our index of contractility) in response to electri-
cal stimulation using a video motion edge detector (IonWizard;
IonOptix). All parameters were evaluated using customized software de-
veloped in the MatLab® platform. Cell shortening from stimulation
(expressed as a percentage of resting cell length), time to peak of shorten-
ing and time to half relaxationweremeasured and calculated as previous-
ly described [22]. We evaluated 32–38 cells per animal in each
experimental group. Only calcium-tolerant, quiescent, rod-shaped
cardiomyocytes showing clear cross striations were studied.
2.6. Statistical analysis
Statistical analysis was performed using Graph-Pad Prism 4
(GraphPad Software, Inc.). Data are reported asmean±SEM. Signiﬁcant
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Fig. 1. Hemodynamic parameters in Wistar rats before (control) and after tonin infusion (5000 ng/kg, iv). A) DAP, diastolic arterial pressure, B) SAP, systolic arterial pressure and
C) MAP, mean arterial pressure. Values are expressed as mean±SEM and n=5 for each group. *pb0.05 and **pb0.01 compared with basal condition (paired Student's t test).
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32 D.D. Damasceno et al. / Regulatory Peptides 181 (2013) 30–36statistical differences were determined with One-way ANOVA followed
by the Newman–Keuls post-test or the Dunnett's post-test, ANOVA one
way onRanks plusDunn's, Two-wayANOVA followed by the Bonferroni
post-test or Student's t-test. Values of pb0.05 were considered to be
statistically signiﬁcant.
3. Results
As compared with control (basal conditions), Wistar rats presented
signiﬁcantly higher DAP andMAP after tonin injection (Fig. 1). The basal
values for DAP, SAP and MAP were 102±4 mm Hg, 135±4 mm Hg
and 120±3 mm Hg, respectively. After injection of the enzyme, a sig-
niﬁcant elevation of DAP (122±2 mm Hg; pb0.01) and MAP (132±
1 mm Hg; pb0.05) was observed. Increase in the HRwas also observed
(Fig. 2). The values of HR were 371±12 bpm in basal condition (con-
trol) and 506±17 bpm [maximum heart rate (HRmax)] after tonin in-
fusion. Increase in HR and BP was observed 1 min after tonin infusion.
However, the increase in HR remained elevated, lasts for longer than
10 min.
Increased BP and HR are associated with decreased HRV. Therefore,
to better understand the physiological role of tonin in the dynamic au-
tonomic regulation of HR, we examined the effects of intravenous ad-
ministration of tonin upon HRV in Wistar rats. Time- and frequency-
domain HRV analyses were conducted under basal condition and after
tonin infusion (5000 ng/kg, iv). Time domain analysis of HRV before
tonin infusion showed higher values when compared with values
after infusion (SDNN: 4.76±0.65 vs 1.06±0.16 ms, n=5, pb0.01;
RMSSD: 5.00±0.67 vs 1.90±0.51 ms, n=5, pb0.01, Student's t-test).
Additionally, the frequency-domain analysis of HRV evidenced an im-
balance of the autonomic control with a signiﬁcant difference between
LF power (%) (Fig. 3A), and no signiﬁcant differences in HF power (%)
were observed (Fig. 3B). However, differences in LF power (%) and HF
power (%) contribute to a signiﬁcant increased in LF/HF ratios (Fig. 3C).
These data evidenced an increase in the sympathetic tone after tonin5 10 15 20 25
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Fig. 2. Changes in heart rate (ΔHR in beats per minute) in freely moving Wistar rats
before (control—time 0) and after tonin infusion (5000 ng/kg, iv). Values are expressed as
mean±SEM and n=5 for each group. **pb0.01 compared with control (Two-way ANOVA
followed by the Bonferroni post-test).infusion. Taken together, these ﬁndings suggest that tonin may cause
an imbalance of the autonomic control of the heart with increases in
the sympathetic tone.
The ECG analysis revealed that after tonin infusion Wistar rats
presented shorter RR interval (Fig. 4A), reﬂecting the higher HR seen
in these animals. A shortening of the QT interval was also observedbefore after
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Fig. 3. Power spectral indexes (LF and HF powers) before and after tonin infusion
(5000 ng/kg, iv). A) Low-frequency spectral power B) high-frequency spectral power
and C) relation LF/HF. Values are mean±SEM, n=5 for each group. **pb0.01 compared
with basal condition (paired Student's t test).
RR interval
0 5 10 15 20 min
0
100
125
150
175
200
**
**
**m
s
PR interval
0 5 10 15 20 min
0
10
20
30
40
50
m
s
QTc
0 5 10 15 20 min
0
50
55
60
65
m
s
QT interval
0 5 10 15 20 min
0
60
65
70
75
80
** **m
s
QRS complex
0 5 10 15 20 min
0
10
20
30
40
50
m
s
A B
D
E
C
Fig. 4. Electrocardiographic parameters in freely moving Wistar rats before (control—time 0) and after tonin infusion (5000 ng/kg, iv). A) RR interval, B) PR interval, C) QT interval,
D) QTc interval and E) QRS complex. Values are expressed as mean±SEM, n=4 for each group. **pb0.01 compared with control (One-way ANOVA followed by the Dunnett's
post-test).
33D.D. Damasceno et al. / Regulatory Peptides 181 (2013) 30–36after tonin infusion (Fig. 4C), even though QT parameters corrected for
HR (QTc)were not different (Fig. 4D). TheQRS complex (Fig. 4E) and PR
interval (Fig. 4B) did not differ from the control, indicating that the
atrioventricular nodal conduction and ventricular conductionwere nor-
mal after tonin injection.
Isolated rat hearts perfusedwith KRS plus tonin presented an increase
in the ACP (Fig. 5A) and reduction in the ventricular systolic tension (ST)
(Fig. 5B)when compared to the control (isolated rat hearts perfusedwith
KRS without tonin). Maximal (dT/dt+) and minimal contractility (dT/dt
−)were also recorded (Fig. 5C andD, respectively). The effect of tonin in-
jection upon ACP and ventricular STmay be due to tonin–Ang II releasing
since the effect upon ACPwas completely blocked by previously adminis-
tered candesartan (Fig. 6) and the levels of Ang II in the coronary sinus ef-
ﬂuent increased in a dose-dependent manner after tonin injection
(Fig. 7). Levels of Ang II ranged from 19.0±2.3×10−10 mol/L before
tonin injection to 33.0±4.0×10−10 mol/L and 60.0±5.0×10−10 mol/L
after tonin injection at 16 ng/mL and 64 ng/mL, respectively.
To determine if the decrease in ST of isolated heart induced by tonin
is occurring at the cellular levelwe examined cell contractile function in
ventricular myocytes freshly isolated from Wistar rats. The results
showed alteration in the rates of contraction and relaxation ofmyocytes
due to the presence of tonin. The time to peak of cell shortening was
signiﬁcantly reduced (Fig. 8B) and the time to half relaxationwas signif-
icantly faster (Fig. 8C). However, no changes were observed upon ino-
tropic effect (cell shortening, Fig. 8A).4. Discussion
In the present study it was observed that femoral injection of tonin
into Wistar rat induces signiﬁcant increase in the DAP, MAP and HR.
Pressor and HR effects of tonin were already described by Araujo et al.
[11]. These authors observed signiﬁcant elevation of MAP (20–30% of
basal value) with simultaneous increase in HRwhen tonin was injected
into the third ventricle of the brain.
The tachycardia observed by us in this study may be due to an in-
crease in the intrinsic heart rate caused by increased sympathetic tone
and augment in the activity levels of the components of the RAS.
Machado and Brody [23] reported that the tachycardia can be directly
related to the intrinsic heart rate increase arising from increased sym-
pathetic tone. Changes in cardiac autonomic balance with predomi-
nance of parasympathetic over sympathetic tone were evidenced as
the determinant of the basal HR.
Tonin activity is characterized by the release of the vasoconstrictor
peptide Ang II [9] that in turn causes acutely, increase in BP by acting di-
rectly to constrict vascular smoothmuscle. Greater increase in the diur-
nal BP (ΔMAP=37±1.8 mm Hg), determined by telemetry in Wistar
rat was observed with continuous Ang II infusion (6 μg/h) [24]. Xu
and Sved [25] observed that the Ang II-induced increase in MAP was
accompanied by bradycardia while the results of the present study
demonstrate tachycardia, probably due to stimulation of sympathetic
outﬂow.
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nous injection of tonin increased the LF component of the HRV. These
results suggested the possibility that tonin infusion increased sympa-
thetic tone and caused an imbalance of autonomic control of the heart.
Abnormal cardiac autonomic control includinghigh levels of sympathet-
ic activity and impaired parasympathetic control is associated with car-
diac dysfunction [26].
In anesthetized rabbits, Kawada et al. [27] demonstrated that the
disproportional suppression of the dynamic vagal and sympathetic
regulation of HR would result in a relative sympathetic predominance
in the presence of Ang II. Akselrod et al. [28] observed that the RASmod-
ulates the amplitude of the spectral peak located at 0.04 Hz and the
authors suggest that the LF peak is related to cyclic ﬂuctuations in
peripheral vasomotor tone. In accordance with Kawada et al. [27], the
reduced HF component of HRV in patients with cardiovascular diseases
may be explained at least in part by the peripheral effects of Ang II
on the dynamic autonomic regulation of HR. Evidence has also been
provided that Ang II plays a facilitatory role on the neuroadrenergic
transmission across sympathetic ganglia; potentiates norepinephrine5 10 15
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Fig. 6. ΔMCP (mean coronary pressure) in isolated heart of Wistar rat in the presence of
tonin, candesartan and tonin-plus-candesartan. Values are expressed as mean±SEM.
n=5 for each group. Tonin compared with candesartan and tonin-plus-candesartan=
***pb0.001 (Two-way ANOVA followed by the Bonferroni post-test).release fromsympathetic nerve terminals via stimulation of presynaptic
angiotensinergic receptors, and expands the alpha-receptor mediated
vasoconstrictor responses to exogenously administered or endogenous-
ly produced norepinephrine [29,30].
Patil et al. [31] observed that distinct colocalization of neuronal Ang
II with dopamine-β-hydroxylase in the heart may indicate that Ang II
participates together with norepinephrine in the regulation of cardiac
functions: Produced as a cardiac neurotransmitter Ang II may have ino-
tropic, chronotropic or dromotropic effects in atria and ventricles and
contributes to blood pressure regulation [31]. Direct vasoconstrictor ef-
fects of Ang II on the coronary vasculature through binding to the AT1
receptor, may importantly inﬂuence myocardial perfusion [32] and in-
duce negative inotropic effects [33]. In the present study, tonin induced
coronary vasoconstriction and at the same time depressed myocardial
contractility.To T16 T64
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Fig. 7. Angiotensin II levels in the coronary sinus efﬂuent before (To) and after tonin per-
fusion at 16 ng/mL (T16) and 64 ng/mL (T64). Values are expressed asmean±SEM. n=5
for each group. **pb0.01 compared with control (T0) (One-way ANOVA followed by the
Newman–Keuls post-test).
Fig. 8. Cell contractile function in isolated left ventricular myocytes. Data are expressed as
mean±SEM. *pb0.05 vs 5, 10, 15 and 20 ng/mL. #pb0.05 vs 10 and 15 ng/mL. ANOVA
one way on Ranks plus Dunn's (n=32 to 38 cells). r.c.l., resting cell length.
35D.D. Damasceno et al. / Regulatory Peptides 181 (2013) 30–36This large heterogeneity in the type of inotropic response to Ang II
in cardiac muscle suggests the possibility that the ﬁnal effect of Ang II
on cardiac excitation–contraction coupling and inotropismmay result
from a complex balance between several opposing mechanisms. The
negative contractile effect of the peptide was observed in the rat
heart [33], papillary muscles of infarcted and noninfarcted rats [34]
and in cardiac myocytes [35]. Infusion of Ang II at 1 μM produces a
negative inotropic effect that is not associated with an observed par-
allel decrease in the intracellular Ca2+ transient, indicating that the
decrease in myoﬁlament responsiveness to Ca2+ levels underlies the
reduction in contractility [35].
Decrease in ST may be correlated with coronary pressure. Downey
[36] observed in his studies that decrease in total coronary blood ﬂow
reduces contractile force. In accordance with Schulz and Heusch [37],
left ventricular mechanical function is very sensitive to reductions in
left coronary blood ﬂow and Morita et al. [38] demonstrated that
α-adrenergic-mediated left coronary vasoconstriction reduced systolic
retrograde coronary ﬂow.
The effects of tonin upon ACPwere completely blocked by previous-
ly administered candesartan. Candesartan selectively blocks the AT1 re-
ceptor [39], therefore, unaltered levels of coronary pressure before
exposure to tonin in the presence of candesartan strongly suggest that
the observed effects are speciﬁcally mediated by tonin–Ang II genera-
tion. Ang II was detectable under control conditions but promptly
increased after the addition of tonin. Probably Ang II was formed by
the action of tonin upon locally present substrate. Lindpaintner et al.
[40] demonstrate that perfusion of the isolated, beating heart with
renin causes dose-dependent appearance of Ang II in the coronary
sinus efﬂuent and that local synthesis is capable of responding to regu-
latory stimulation.
Altered Ca2+ handling can inﬂuence cardiomyocyte physiology
and changes in intracellular Ca2+ are a major feature in heart failure
and myocyte pathology [41]. To determine if the decrease in ST in iso-
lated heart after tonin infusion is related to changes in cellular con-
tractile function, we examined mechanical parameters in freshly
isolated left ventricular myocytes from Wistar rats perfused withdifferent tonin concentrations. Although the direct inotropic effect
(cell shortening) of tonin was not observed, alterations in the veloci-
ties of contraction and relaxation were observed after tonin perfu-
sion. The time to peak of cell shortening was signiﬁcantly reduced
and the time to half relaxation was signiﬁcantly faster. This is an indi-
cation that Ca2+ handling is accelerated by tonin. For instance, the
faster the Ca2+ release and re-uptake by the sarcoplasmic reticulum
in rat left ventricular myocytes the faster the cell shortening and re-
laxation, respectively [42].
In conclusion we demonstrated that intravenous infusion of tonin
in the rat affects BP and HR. Tonin is able to generate the pressor oc-
tapeptide Ang-II in the isolated rat heart and the cardiovascular (ACP,
ST and HR) responses induced by tonin were completely blocked by
candesartan, an indication that the action of Ang II on AT1 receptors
is the major mechanism of the heart effects.
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